Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179043 | 0.88 | OPRD1 (0.40) | OPRD1OPRK1OPRM1 | |
| SCHEMBL13394992 | 0.88 | OPRD1 (0.40) | OPRD1OPRK1OPRM1 | |
| SCHEMBL13395057 | 0.88 | OPRD1 (0.40) | OPRD1OPRK1OPRM1 | |
| SCHEMBL5125347 | 0.86 | OPRD1 (0.44) | OPRD1OPRK1OPRM1 | |
| SCHEMBL5119775 | 0.86 | OPRD1 (0.46) | OPRD1OPRK1OPRM1 | |
| SCHEMBL5112789 | 0.84 | OPRD1 (0.51) | OPRD1OPRK1OPRM1 | |
| SCHEMBL5111751 | 0.84 | OPRD1 (0.46) | OPRD1OPRK1OPRM1 | |
| SCHEMBL5112226 | 0.83 | OPRD1 (0.44) | OPRD1OPRK1OPRM1KMT2A | |
| SCHEMBL14015424 | 0.83 | ADRA1D (0.38) | OPRD1OPRK1OPRM1 | |
| SCHEMBL5125316 | 0.81 | OPRD1 (0.45) | OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | claimed |
| US-20060148823-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | claimed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-20060148823-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148823-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885OPRK1 2/4885OPRM1 4/4885 |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885OPRK1 2/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.